Cancer immunotherapy company Provecs Medical GmbH and oncology pharma Medac GmbH have announced a collaboration to take forward a product for urinary bladder cancer and other solid cancers.
The privately-held German partners aim to develop, manufacture and market Provec’s cancer immunotherapy lead product Immunalon. They have not disclosed financial details of the deal.
“We are seeking partners for the development of Immunalon in other solid cancer indications with high medical need and a lack of standard therapies.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze